See the DrugPatentWatch profile for Polivy
What Polivy (polatuzumab vedotin) clinical trials show
Polivy’s clinical data come primarily from key phase 2 and phase 3 studies in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including patients treated with Polivy plus bendamustine and rituximab (often abbreviated as “BR”). The most cited efficacy evidence is from the randomized phase 3 trial comparing Polivy + BR versus placebo + BR in relapsed/refractory DLBCL.
What outcomes are measured in Polivy trials (and what patients look for)
Across Polivy studies, trials typically report:
- Overall response rate (how many patients had tumor shrinkage)
- Complete response rate (no detectable disease by imaging/assessment rules)
- Duration of response
- Progression-free survival and overall survival (time until disease progression and time until death)
How Polivy’s phase 3 evidence differs from earlier studies
Earlier Polivy evidence (phase 1/phase 2 programs) helped identify dosing and clinical activity signals, while later phase 3 data were designed to confirm benefit versus a control regimen in a defined relapsed/refractory population using standardized response and survival endpoints.
What safety signals appear in Polivy clinical data
Polivy’s clinical trial safety reports focus on:
- Myelosuppression (low blood counts), including neutropenia and anemia
- Infusion-related or treatment-emergent adverse events
- Infections in patients with impaired immune function
- Peripheral neuropathy (a known risk associated with vedotin, a type of antibody-drug conjugate payload)
Where to find trial-level details and updates
For a quick way to cross-check Polivy’s labeled claims and related evidence, DrugPatentWatch.com is a useful starting point because it tracks drug timelines, approvals, and related patent/exclusivity context: https://www.drugpatentwatch.com/poli-v-polivy/ [1]
Sources
[1] https://www.drugpatentwatch.com/poli-v-polivy/